Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
about
Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditisFluconazole pharmacokinetics in burn patientsOutcome assessment of minimizing vancomycin monitoring and dosing adjustments.Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infectionsPharmacokinetics of cefepime in patients with thermal burn injury.Pharmacokinetics of vancomycin in adult cystic fibrosis patients.Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.Infective Endocarditis in Intravenous Drug Abusers.Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding.Daptomycin.Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin.Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury.Aztreonam pharmacokinetics in burn patientsAugmented renal clearance: implications for antibacterial dosing in the critically ill.Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.Pharmacokinetics and pharmacodynamics of antibacterial and antifungal agents in adult patients with thermal injury: a review of current literature.A Systematic Review of Vancomycin Dosing and Monitoring in Burn Patients.Gap analysis of pharmacokinetics and pharmacodynamics in burn patients: a review.Vancomycin therapeutic drug monitoring: is it necessary?How to use vancomycin optimally in neonates: remaining questions.Population pharmacokinetic parameters of vancomycin in critically ill patients.Glycopeptides and nephrotoxicity.A closer look at vancomycin, teicoplanin, and antimicrobial resistance.Pharmacokinetics of vancomycin in adult cancer patients.Augmented renal clearance of vancomycin and levetiracetam in a traumatic brain injury patient.Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy.Nephrotoxicity in patients with vancomycin trough concentrations of 15-20 μg/ml in a pediatric intensive care unit.Population pharmacokinetics of arbekacin in burn patients.High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures.Vancomycin protein binding in patients with infections caused by Staphylococcus aureus.
P2860
Q24645282-85EBB058-447B-4721-AFC2-69A0BA9EDBB6Q33692868-DE66992C-6AF9-4C67-92B0-4E22882AC39EQ33860155-DA8098FD-6893-486E-BF25-B00E51F2B4BEQ33881584-05070A7B-908E-4B22-A489-B01EC72BA5AFQ33978205-D06A9FE1-A749-4A35-91D3-0DF063799EA5Q35121949-8F80B678-0E83-4899-BAA4-6C4868879AF9Q35123139-33AA1102-7A5D-4560-973D-71E12F2F778CQ35123155-4F0EDC80-3AA4-43B2-8978-EA4B2D7C76D8Q35179332-91B836A4-6892-4BEC-8CA8-F836BD2C09D9Q35191519-309F12DB-DA58-44E7-817A-A6C568054695Q35637066-D741345C-62E7-4F31-BF7C-8887444D0460Q35809992-FDAEB5E1-EE71-4D40-A55D-B5C246927079Q35836523-09CCE56D-C531-45BD-9397-A738B62DF5E2Q35862551-36261C98-73F3-4883-8F47-78DAC6E24D18Q36363239-627B5233-9FB0-4810-AEE9-A5AFF740FC15Q36752546-021DC83E-876E-45C3-AF35-D813A16E5051Q37650115-3FF645D1-A658-42A3-B632-EEFACC087090Q38000242-A5622969-0E74-4B50-BDA8-FCBD4E92E5BCQ38244221-EE072289-5772-4F58-A48A-D4E71BCA759FQ38271273-A8030235-1A1E-4C97-A3A2-035821B9A177Q38459977-45E5EB92-70E2-4E0C-8B0F-816E531175D7Q38566835-ED9EC31D-6245-4778-AE33-16D9419749F0Q38569678-AD4EBC93-AC90-46E3-B47F-AB79B44D17DAQ40290397-D8CB37DB-CB4E-42F1-BB86-A4A60A03EAE5Q40495778-9659DAFE-0756-41D6-A6DD-212239071265Q41646436-C115B407-86BC-49AA-B318-7378EBB02D07Q42643110-A2AFC320-5FB6-42A6-879D-9625224BF017Q43980511-A64F8145-8FCA-4F11-B859-4624D068CE87Q43984406-A72F5401-06A9-43F9-B8D4-ED0E234E7E66Q45083281-1393EEE5-06DD-4A24-B222-12012895C16FQ45329118-84ACB275-8449-4F03-BED2-8BECD43EDB34Q46718647-FBEED132-F726-4853-BCE8-507D50740C2CQ52081441-48BBB102-443C-4C6E-ABD1-A8F15310F320Q54292737-56012C81-E5FA-4DA3-8654-D30E23B62A28
P2860
Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
description
1990 nî lūn-bûn
@nan
1990 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
@ast
Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
@en
type
label
Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
@ast
Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
@en
prefLabel
Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
@ast
Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
@en
P2093
P2860
P356
P1476
Vancomycin pharmacokinetics in burn patients and intravenous drug abusers
@en
P2093
Albrecht LM
Svensson CK
Warbasse LH
P2860
P304
P356
10.1128/AAC.34.5.792
P407
P577
1990-05-01T00:00:00Z